Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) announced management participation in three investor conferences in October 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) announced management participation in three investor conferences in October 2025. CTXR management will attend LD Micro Main Event XIX (Oct 19-21, 2025) in San Diego and the Think Equity Conference (Oct 30, 2025) in New York. CTOR management will attend the 2025 Maxim Growth Summit (Oct 22-23, 2025) in New York.
Both companies said investors may request 1-on-1 meetings via the event platforms or by contacting the companies' investor relations teams; CTOR noted scheduled meetings with institutional investors and Maxim senior analysts.
Details
News Market Reaction – CTOR
On Oct 20, the first trading day after this news, CTOR closed 5.29% above the previous close.
Data tracked by StockTitan Argus for the Oct 20 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LD Micro Main Event XIX, October 19-21, 2025
2025 Maxim Growth Summit, October 22-23, 2025
The Think Equity Conference, October 30, 2025
Citius Pharmaceuticals (Nasdaq: CTXR)
|
Event: |
LD Micro Main Event XIX |
|
Date: |
October 19-21, 2025 |
|
Location: |
Hotel Del Coronado, |
|
Event website: |
|
|
|
|
|
|
|
|
Event: |
Think Equity Conference |
|
Date: |
October 30, 2025 |
|
Location: |
Mandarin Oriental, |
|
Event website: |
|
Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company's investor relations team.
Citius Oncology (Nasdaq: CTOR)
|
Event: |
2025 Maxim Growth Summit |
|
Date: |
October 22-23, 2025 |
|
Location: |
The Hard Rock Hotel, |
|
Event website: |
Citius Oncology will be meeting with institutional investors in a one-on-one format, and senior Maxim analysts during the event.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns
About Citius Oncology, Inc.
Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-and-citius-oncology-to-participate-in-upcoming-october-2025-conferences-302586084.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.